These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19097891)

  • 41. Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes.
    Weiland F; Verspohl EJ
    Horm Metab Res; 2008 Nov; 40(11):760-6. PubMed ID: 18711690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sakuranetin induces adipogenesis of 3T3-L1 cells through enhanced expression of PPARgamma2.
    Saito T; Abe D; Sekiya K
    Biochem Biophys Res Commun; 2008 Aug; 372(4):835-9. PubMed ID: 18522800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Matrix metalloproteinase-3 enhances the free fatty acids-induced VEGF expression in adipocytes through toll-like receptor 2.
    Kawamura T; Murakami K; Bujo H; Unoki H; Jiang M; Nakayama T; Saito Y
    Exp Biol Med (Maywood); 2008 Oct; 233(10):1213-21. PubMed ID: 18641052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effects of berberine on adiponectin mRNA expression in 3T3-L1 adipocyte].
    Gu W; Zeng WH; Hu HY
    Zhongguo Zhong Yao Za Zhi; 2005 Feb; 30(4):286-8. PubMed ID: 15724409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and synthesis of a bis(cycloisodityrosine) analogue of RA-VII, an antitumor bicyclic hexapeptide.
    Lee JE; Hitotsuyanagi Y; Nakagawa Y; Kato S; Fukaya H; Takeya K
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6458-61. PubMed ID: 18993061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors.
    Barf T; Lehmann F; Hammer K; Haile S; Axen E; Medina C; Uppenberg J; Svensson S; Rondahl L; Lundbäck T
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1745-8. PubMed ID: 19217286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery and optimization of a novel Neuromedin B receptor antagonist.
    Fu J; Shuttleworth SJ; Connors RV; Chai A; Coward P
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4264-7. PubMed ID: 19553112
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effects of Rehmannia glutinosa oligosaccharides on proliferation of 3T3-L1 adipocytes and insulin resistance].
    Guo XN; Zhang RX; Jia ZP; Li MX; Wang J
    Zhongguo Zhong Yao Za Zhi; 2006 Mar; 31(5):403-7. PubMed ID: 16711427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.
    Tang J; Hamajima T; Nakano M; Sato H; Dickerson SH; Lackey KE
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4610-4. PubMed ID: 18662874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives.
    Lu SF; Chen B; Davey D; Dunning L; Jaroch S; May K; Onuffer J; Phillips G; Subramanyam B; Tseng JL; Wei RG; Wei M; Ye B
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1883-7. PubMed ID: 17314043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isolation of 9-hydroxy-10E,12Z-octadecadienoic acid, an inhibitor of fat accumulation from Valeriana fauriei.
    Yuki K; Ikeda M; Miyamoto K; Ohno O; Yamada K; Uemura D
    Biosci Biotechnol Biochem; 2012; 76(6):1233-5. PubMed ID: 22790953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Image-based high-throughput quantification of cellular fat accumulation.
    Dragunow M; Cameron R; Narayan P; O'Carroll S
    J Biomol Screen; 2007 Oct; 12(7):999-1005. PubMed ID: 17942793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conformationally restricted analog and biotin-labeled probe based on beauveriolide III.
    Doi T; Muraoka T; Ohshiro T; Matsuda D; Yoshida M; Takahashi T; Omura S; Tomoda H
    Bioorg Med Chem Lett; 2012 Jan; 22(1):696-9. PubMed ID: 22079027
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Solution-phase parallel synthesis of a pharmacophore library of HUN-7293 analogues: a general chemical mutagenesis approach to defining structure-function properties of naturally occurring cyclic (depsi)peptides.
    Chen Y; Bilban M; Foster CA; Boger DL
    J Am Chem Soc; 2002 May; 124(19):5431-40. PubMed ID: 11996584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of new inhibitor for PDE3 by virtual screening.
    Kim KY; Lee H; Yoo SE; Kim SH; Kang NS
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1617-20. PubMed ID: 21330134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Form and function in cyclic peptide natural products: a pharmacokinetic perspective.
    Bockus AT; McEwen CM; Lokey RS
    Curr Top Med Chem; 2013; 13(7):821-36. PubMed ID: 23578026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strategies for Fine-Tuning the Conformations of Cyclic Peptides.
    Jwad R; Weissberger D; Hunter L
    Chem Rev; 2020 Sep; 120(17):9743-9789. PubMed ID: 32786420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of crystallography in drug design.
    Deschamps JR
    AAPS J; 2005 Dec; 7(4):E813-9. PubMed ID: 16594633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug discovery on the assembly line.
    Alper J
    Science; 1994 Jun; 264(5164):1399-401. PubMed ID: 8197450
    [No Abstract]   [Full Text] [Related]  

  • 60. Toward the elucidation of the mechanism for passive membrane permeability of cyclic peptides.
    Riniker S
    Future Med Chem; 2019 Apr; 11(7):637-639. PubMed ID: 30920310
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.